NBN
About
Location: 8q21.3
Mappings
Biomarkers
NBN is involved in the following curated biomarkers.
| Name | Biomarker type | Propositions | Statements |
|---|---|---|---|
| NBN oncogenic variants | Somatic Variant | 1 | 1 |
| NBN pathogenic variants | Germline Variant | 1 | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response involving this gene.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | NBN oncogenic variants | Prostate Adenocarcinoma | Enzalutamide, Talazoparib | |
| FDA (1) | NBN pathogenic variants | Prostate Adenocarcinoma | Enzalutamide, Talazoparib |